Table 1.
Baseline demographics and disease characteristics (data for the safety analysis set, n = 71 and for the effectiveness analysis set, n = 68).
| Safety analysis set (n = 71) | Effectiveness analysis set (n = 68) | |
|---|---|---|
| Age, years, mean (SD) | 50.7 (13.3) | 50.6 (13.2) |
| Female, n (%) | 67 (94.4) | 64 (94.1) |
| Disease duration, years, mean (SD) | 6.8 (6.2) | 6.9 (6.3) |
| <2 years, n (%) | 20 (28.2) | 20 (29.4) |
| ⩾2 years, n (%) | 51 (71.8) | 48 (70.6) |
| Symptoms at NMOSD diagnosis, n (%) | ||
| Optic neuritis | 34 (47.9) | 32 (47.1) |
| Transverse myelitis | 35 (49.3) | 34 (50.0) |
| Brain stem symptoms | 15 (21.1) | 14 (20.6) |
| Cerebral symptoms | 5 (7.0) | 5 (7.4) |
| Other | 2 (2.8) | 2 (2.9) |
| Any relapse in the 2 years before eculizumab administration, n (%) | 51 (71.8) | 51 (75.0) |
| Relapse count in the 2 years before eculizumab administration, n (%) | ||
| 1 | 22 (43.1) | 22 (43.1) |
| 2 | 14 (27.5) | 14 (27.5) |
| 3 | 9 (17.6) | 9 (17.6) |
| ⩾4 | 6 (11.8) | 6 (11.8) |
| Terminal complement protein C5 genetic polymorphism, n (%) | ||
| Positive | 0 (0.0) | 0 (0.0) |
| Negative | 27 (38.0) | 27 (39.7) |
| Not measured | 42 (59.2) | 39 (57.4) |
| Blank | 0 (0.0) | 0 (0.0) |
| Meningococcal vaccination received, n (%) | 70 (98.6) | 67 (98.5) |
| Prior NMOSD treatment, n (%) | ||
| Steroids | 69 (97.2) | 66 (97.1) |
| Immunosuppressive therapy | 40 (56.3) | 40 (58.8) |
| Plasma exchange | 28 (39.4) | 27 (39.7) |
| Intravenous immunoglobulin | 5 (7.0) | 5 (7.4) |
| Biologics | 3 (4.2) | 3 (4.4) |
| Other | 17 (23.9) | 16 (23.5) |
NMOSD, neuromyelitis optica spectrum disorder; SD, standard deviation.